Do the benefits of Opzelura (Ruxolitinib) outweigh the potential risks? An insight into the FDA-approved treatment for non-segmental vitiligo (NSV)

Abstract

Recently, Ruxolitinib (Opzelura) has been approved by the Food and Drug Administration (FDA) as the first treatment for non-segmental vitiligo, which results in chalky white macules with clear edges due to an autoimmune disorder. The mode of action of this cream is JAK inhibition which progressively enhances the growth of new, healthy skin cells, and eventually, repigmentation occurs in the affected area. Indeed, this medication represents significance in the field of dermatology as almost 3/4th % of facial vitiligo was resolved but the high cost will be a hindrance in facilitating the patients and should be subsidized. Moreover, prescribers and pharmacists should be aware of the black box warnings issued by FDA as severe caution is indicated. More clinical trials should be conducted to know the safety of children under 12 years of age.